Cargando…
S129: TAKEAIM LEUKEMIA- A PHASE 1/2A STUDY OF THE IRAK4 INHIBITOR EMAVUSERTIB (CA-4948) AS MONOTHERAPY OR IN COMBINATION WITH AZACITIDINE OR VENETOCLAX IN RELAPSED/REFRACTORY AML OR MDS
| Autores principales: | , , , , , , , , , , , , , , , , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Lippincott Williams & Wilkins
2022
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9642083/ http://dx.doi.org/10.1097/01.HS9.0000843408.31385.3f |
| _version_ | 1784826227470630912 |
|---|---|
| author | Garcia-Manero, G. Winer, E. S. DeAngelo, D. J. Tarantolo, S. Sallman, D. A. Dugan, J. Groepper, S. Giagounidis, A. Götze, K. Metzeler, K. H. Li, C.-C. Zhou, L. Martinez, E. Lane, M. von Roemeling, R. Bohme, M. Kubasch, A. S. Verma, A. Platzbecker, U. |
| author_facet | Garcia-Manero, G. Winer, E. S. DeAngelo, D. J. Tarantolo, S. Sallman, D. A. Dugan, J. Groepper, S. Giagounidis, A. Götze, K. Metzeler, K. H. Li, C.-C. Zhou, L. Martinez, E. Lane, M. von Roemeling, R. Bohme, M. Kubasch, A. S. Verma, A. Platzbecker, U. |
| author_sort | Garcia-Manero, G. |
| collection | PubMed |
| description | |
| format | Online Article Text |
| id | pubmed-9642083 |
| institution | National Center for Biotechnology Information |
| language | English |
| publishDate | 2022 |
| publisher | Lippincott Williams & Wilkins |
| record_format | MEDLINE/PubMed |
| spelling | pubmed-96420832022-11-14 S129: TAKEAIM LEUKEMIA- A PHASE 1/2A STUDY OF THE IRAK4 INHIBITOR EMAVUSERTIB (CA-4948) AS MONOTHERAPY OR IN COMBINATION WITH AZACITIDINE OR VENETOCLAX IN RELAPSED/REFRACTORY AML OR MDS Garcia-Manero, G. Winer, E. S. DeAngelo, D. J. Tarantolo, S. Sallman, D. A. Dugan, J. Groepper, S. Giagounidis, A. Götze, K. Metzeler, K. H. Li, C.-C. Zhou, L. Martinez, E. Lane, M. von Roemeling, R. Bohme, M. Kubasch, A. S. Verma, A. Platzbecker, U. Hemasphere Oral Sessions Lippincott Williams & Wilkins 2022-06-23 /pmc/articles/PMC9642083/ http://dx.doi.org/10.1097/01.HS9.0000843408.31385.3f Text en Copyright © 2022 The Author(s). Published by Wolters Kluwer Health, Inc. https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open access Abstract Book distributed under the Attribution-NonCommercial-NoDerivs (CC BY-NC-ND) (https://creativecommons.org/licenses/by-nc-nd/4.0/) which allows third parties to download the articles and share them with others as long as they credit the author and the Abstract Book, but they cannot change the content in any way or use them commercially. |
| spellingShingle | Oral Sessions Garcia-Manero, G. Winer, E. S. DeAngelo, D. J. Tarantolo, S. Sallman, D. A. Dugan, J. Groepper, S. Giagounidis, A. Götze, K. Metzeler, K. H. Li, C.-C. Zhou, L. Martinez, E. Lane, M. von Roemeling, R. Bohme, M. Kubasch, A. S. Verma, A. Platzbecker, U. S129: TAKEAIM LEUKEMIA- A PHASE 1/2A STUDY OF THE IRAK4 INHIBITOR EMAVUSERTIB (CA-4948) AS MONOTHERAPY OR IN COMBINATION WITH AZACITIDINE OR VENETOCLAX IN RELAPSED/REFRACTORY AML OR MDS |
| title | S129: TAKEAIM LEUKEMIA- A PHASE 1/2A STUDY OF THE IRAK4 INHIBITOR EMAVUSERTIB (CA-4948) AS MONOTHERAPY OR IN COMBINATION WITH AZACITIDINE OR VENETOCLAX IN RELAPSED/REFRACTORY AML OR MDS |
| title_full | S129: TAKEAIM LEUKEMIA- A PHASE 1/2A STUDY OF THE IRAK4 INHIBITOR EMAVUSERTIB (CA-4948) AS MONOTHERAPY OR IN COMBINATION WITH AZACITIDINE OR VENETOCLAX IN RELAPSED/REFRACTORY AML OR MDS |
| title_fullStr | S129: TAKEAIM LEUKEMIA- A PHASE 1/2A STUDY OF THE IRAK4 INHIBITOR EMAVUSERTIB (CA-4948) AS MONOTHERAPY OR IN COMBINATION WITH AZACITIDINE OR VENETOCLAX IN RELAPSED/REFRACTORY AML OR MDS |
| title_full_unstemmed | S129: TAKEAIM LEUKEMIA- A PHASE 1/2A STUDY OF THE IRAK4 INHIBITOR EMAVUSERTIB (CA-4948) AS MONOTHERAPY OR IN COMBINATION WITH AZACITIDINE OR VENETOCLAX IN RELAPSED/REFRACTORY AML OR MDS |
| title_short | S129: TAKEAIM LEUKEMIA- A PHASE 1/2A STUDY OF THE IRAK4 INHIBITOR EMAVUSERTIB (CA-4948) AS MONOTHERAPY OR IN COMBINATION WITH AZACITIDINE OR VENETOCLAX IN RELAPSED/REFRACTORY AML OR MDS |
| title_sort | s129: takeaim leukemia- a phase 1/2a study of the irak4 inhibitor emavusertib (ca-4948) as monotherapy or in combination with azacitidine or venetoclax in relapsed/refractory aml or mds |
| topic | Oral Sessions |
| url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9642083/ http://dx.doi.org/10.1097/01.HS9.0000843408.31385.3f |
| work_keys_str_mv | AT garciamanerog s129takeaimleukemiaaphase12astudyoftheirak4inhibitoremavusertibca4948asmonotherapyorincombinationwithazacitidineorvenetoclaxinrelapsedrefractoryamlormds AT wineres s129takeaimleukemiaaphase12astudyoftheirak4inhibitoremavusertibca4948asmonotherapyorincombinationwithazacitidineorvenetoclaxinrelapsedrefractoryamlormds AT deangelodj s129takeaimleukemiaaphase12astudyoftheirak4inhibitoremavusertibca4948asmonotherapyorincombinationwithazacitidineorvenetoclaxinrelapsedrefractoryamlormds AT tarantolos s129takeaimleukemiaaphase12astudyoftheirak4inhibitoremavusertibca4948asmonotherapyorincombinationwithazacitidineorvenetoclaxinrelapsedrefractoryamlormds AT sallmanda s129takeaimleukemiaaphase12astudyoftheirak4inhibitoremavusertibca4948asmonotherapyorincombinationwithazacitidineorvenetoclaxinrelapsedrefractoryamlormds AT duganj s129takeaimleukemiaaphase12astudyoftheirak4inhibitoremavusertibca4948asmonotherapyorincombinationwithazacitidineorvenetoclaxinrelapsedrefractoryamlormds AT groeppers s129takeaimleukemiaaphase12astudyoftheirak4inhibitoremavusertibca4948asmonotherapyorincombinationwithazacitidineorvenetoclaxinrelapsedrefractoryamlormds AT giagounidisa s129takeaimleukemiaaphase12astudyoftheirak4inhibitoremavusertibca4948asmonotherapyorincombinationwithazacitidineorvenetoclaxinrelapsedrefractoryamlormds AT gotzek s129takeaimleukemiaaphase12astudyoftheirak4inhibitoremavusertibca4948asmonotherapyorincombinationwithazacitidineorvenetoclaxinrelapsedrefractoryamlormds AT metzelerkh s129takeaimleukemiaaphase12astudyoftheirak4inhibitoremavusertibca4948asmonotherapyorincombinationwithazacitidineorvenetoclaxinrelapsedrefractoryamlormds AT licc s129takeaimleukemiaaphase12astudyoftheirak4inhibitoremavusertibca4948asmonotherapyorincombinationwithazacitidineorvenetoclaxinrelapsedrefractoryamlormds AT zhoul s129takeaimleukemiaaphase12astudyoftheirak4inhibitoremavusertibca4948asmonotherapyorincombinationwithazacitidineorvenetoclaxinrelapsedrefractoryamlormds AT martineze s129takeaimleukemiaaphase12astudyoftheirak4inhibitoremavusertibca4948asmonotherapyorincombinationwithazacitidineorvenetoclaxinrelapsedrefractoryamlormds AT lanem s129takeaimleukemiaaphase12astudyoftheirak4inhibitoremavusertibca4948asmonotherapyorincombinationwithazacitidineorvenetoclaxinrelapsedrefractoryamlormds AT vonroemelingr s129takeaimleukemiaaphase12astudyoftheirak4inhibitoremavusertibca4948asmonotherapyorincombinationwithazacitidineorvenetoclaxinrelapsedrefractoryamlormds AT bohmem s129takeaimleukemiaaphase12astudyoftheirak4inhibitoremavusertibca4948asmonotherapyorincombinationwithazacitidineorvenetoclaxinrelapsedrefractoryamlormds AT kubaschas s129takeaimleukemiaaphase12astudyoftheirak4inhibitoremavusertibca4948asmonotherapyorincombinationwithazacitidineorvenetoclaxinrelapsedrefractoryamlormds AT vermaa s129takeaimleukemiaaphase12astudyoftheirak4inhibitoremavusertibca4948asmonotherapyorincombinationwithazacitidineorvenetoclaxinrelapsedrefractoryamlormds AT platzbeckeru s129takeaimleukemiaaphase12astudyoftheirak4inhibitoremavusertibca4948asmonotherapyorincombinationwithazacitidineorvenetoclaxinrelapsedrefractoryamlormds |